Takeda To Buy IDM Pharma Of U.S., Maker Of Bone Cancer Drug
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical said it intends to buy U.S. drug maker IDM Pharma for $66.7 million in cash. With the purchase, Takeda expects to get the American firm's Mepact (mifamurtide), a cancer drug for treating osteosarcoma. The drug has yet to be approved by the U.S. FDA, but it recently was cleared for marketing in Europe. Takeda's European CEO said the drug is capable of contributing in the near term to the firm's "top-line growth." (Click here for more
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.